NBIX Dec 2024 115.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 02:15PM EDT. Mercato aperto.
| Chiusura precedente | 28,95 |
| Aperto | 28,95 |
| Denaro | 31,80 |
| Lettera | 36,00 |
| Prezzo d'esercizio | 115,00 |
| Scadenza | 2024-12-20 |
| Min-Max giorno | 28,95 - 28,95 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 7 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.